BSX: Leadership change · Other company developments

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Operating Officer On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027. Mr. Fitzgerald, age 63, joined the Company in 1990, and has held a variety of management positions in the Company’s Cardiovascular business. In his current position, which he has held since May 2022, Mr. Fitzgerald oversees development and commercialization of advanced heart therapies for health care professionals and patients globally. Prior to that, Mr. Fitzgerald served as Executive Vice President and President, Cardiology from January 2022 to April 2022, as Executive Vice President and President, Interventional Cardiology from July 2020 to January 2022, as Executive Vice President and President, Rhythm Management from 2014 to 2020, and as Senior Vice President and President, Cardiac Rhythm Management from 2011 to 2014, as well as various roles of increasing responsibility prior to that. Mr. Fitzgerald is a member of the Company’s Global Council for Inclusion and is executive sponsor of the Company’s Women’s Network employee resource group. Mr. Fitzgerald received an MBA from Southern Illinois University with a concentration in marketing and finance and a BS in business from Indiana University. Under the terms of Mr. Fitzgerald’s offer letter (the “Offer Letter”), effective as of January 1, 2027, as Executive Vice President and Chief Operating Officer, Mr. Fitzgerald will be entitled to th